Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome.
- Author:
Xiao-yan ZHENG
1
;
Ling LIU
;
Shui-ping ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Acute Coronary Syndrome; drug therapy; metabolism; physiopathology; Adult; Aged; Anticholesteremic Agents; therapeutic use; Atorvastatin Calcium; C-Reactive Protein; metabolism; Cholesterol, LDL; blood; Drug Therapy, Combination; Endothelium, Vascular; drug effects; metabolism; Female; Heptanoic Acids; therapeutic use; Humans; Male; Middle Aged; Probucol; therapeutic use; Pyrroles; therapeutic use
- From: Chinese Journal of Cardiology 2009;37(10):900-903
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo evaluate the effects of combined atorvastatin and probucol use on endothelial function in patients with acute coronary syndrome (ACS).
METHODSThirty patients with ACS were randomized to receive atorvastatin (20 mg/d) and probucol (500 mg/d, combination group, n = 15) or atorvastatin (20 mg/d) alone (atorvastatin group) within 24 h after admission for 4 weeks. Endothelium-dependent flow-mediated dilatation (FMD) and endothelium-independent sublingual nitroglycerin-mediated dilatation (NMD) as well as the levels of lipids and C-reactive protein were assessed at baseline, 1 week and 4 weeks after therapy.
RESULTSCompared to baseline, the levels of total cholesterol, LDL-C and C-reactive protein were significantly reduced after 1 week and 4 weeks in both groups, FMD equally increased after 1 week in both groups (atorvastatin group: 3.75% +/- 0.78% vs. 1.09% +/- 0.44%, combination group: 3.67% +/- 0.36% vs. 1.24% +/- 0.37%, P < 0.01). Post 4 weeks therapy, FMD increase was significantly higher in combination group (3.67% +/- 0.36% at 1 week vs. 6.85% +/- 0.64% at 4 weeks, P < 0.01) than that in atorvastatin group (3.75% +/- 0.78% vs. 3.80% +/- 0.31%, P = 0.954). NMD also equally and increased over 4 weeks in two groups (P < 0.01 vs. baseline). There was no correlation between the change in FMD/NMD and the changes in lipids or C-reactive protein levels.
CONCLUSIONSThe combined atorvastatin and probucol therapy early after ACS is superior to atorvastatin alone on improving endothelial function.
